Prime Medicine, Inc. is a biotechnology company that delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein and a pegRNA, and has research collaborations for developing therapies for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

COM:PRIMEMEDICINE

Prime Medicine, Inc.

Last Close

2.99

21/11 15:29

Market Cap

666.17M

Beta: -

Volume Today

264.32K

Avg: -

market

industry

website

crunchbase

ipo date

investor of

competitor of

Metrics